AMAG Pharmaceuticals, Inc. to Host Conference Call on February 9, 2015 at 4:30 p.m. ET to Discuss Financial Results for the Quarter and Year Ended 2014

WALTHAM, Mass., Feb. 3, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014 on Monday, February 9, 2015 after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with slides at 4:30 p.m. ET during which management will discuss the company's financial results, business update, regulatory status, and growth prospects.

To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 7:30 p.m. ET on February 9, 2015 through midnight on February 16, 2015. To access a replay of the conference call, dial (855) 859-2056 from the United States or (404) 537-3406 for international access. The pass code for the live call and the replay is 80800854.

The call will be webcast with slides and accessible through the Investors section of the company's website at www.amagpharma.com. The webcast replay will be available from approximately 7:30p.m. ET on February 9, 2014 through midnight March 10, 2014.

About AMAG

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company with a focus on maternal health, anemia and cancer supportive care. The primary goal of AMAG and its maternal health division, Lumara HealthTM, is to bring to market therapies that provide clear benefits and improve patients' lives. In addition to continuing to pursue opportunities to make new advancements in patients' health and to enhance treatment accessibility, AMAG intends to continue to expand and diversify its portfolio through the in-license or purchase of additional pharmaceutical products or companies. For additional company information, please visit www.amagpharma.com.

CONTACT: AMAG Pharmaceuticals, Inc. Katie Payne, 617-498-3303

Source:AMAG Pharmaceuticals, Inc.